phone icon  Int'l : +1-503-894-6022
0
Shopping Cart is Empty..
$ 0

World Biosimilars/Follow-on-Biologics Market

- Opportunities and Forecasts, 2013 - 2020
 Report Code: LI 14162
 Pages: 184
 Format: PDF Exel CD_rom
pub_n Published: Jul 2014
tab_nTables: 54
aut_nAuthor(s):

Biosimilars or follow-on-biologics are the “copied” version of reference biologics, which are protected by intellectual rights that will expire soon. Patent expiration is the major driving factor of the market. Most of the blockbuster patents will expire by the end of 2014, which would provide a competitive edge to local pharmaceutical manufacturers over the global players. For instance, patents for insulin glargine will expire by the end of this year, which would give an opportunity for the growth of insulin biosimilars market. Global biosimilars/follow-on-biologics market accounted for $1,358 million in 2013 and it is anticipated to generate $35,032 million by 2020, growing at a CAGR of 60.8% from 2014 to 2020. Biosimilar medicines have witnessed growth over the past five and six years. 

Regulations for this biologic medical product plays a vital role in maintaining the viability and balance between original and biosimilar products. Various regulatory authorities, namely EMA and the U.S. FDA are actively regulating the global biosimilars market. Regulations in the European union are considered benchmark around the world, as the guidelines proposed are most stringent for validation and commercialization of biosimilars. High profitability is the attractive aspect that is enticing companies to invest in the biosimilars industry. 

Geographically, Biosimilars market is segmented into North America, Europe, Asia-Pacific and LAMEA. Due to favorable regulatory policies designed by the European Medical Association, the European market has been maximizing on the market. Asia-Pacific and LAMEA market would witness a substantial rise in the use of biosimilars, as the demand for cost effective treatment is growing due to the prevalence of chronic diseases. Collaboration with local players would be a key opportunity that could be fully explored by the biosimilars manufacturers in developing economies. Many companies such as Amgen and Novartis are collaborating with Asian players to gain a foothold in the biopharmaceutical market. 

Europe was the first region to draft guidelines for approval of biosimilars in 2006. Nevertheless, in 2008, the first biosimilars version of Granulocyte colony-stimulating factor (G-CSF) was introduced in the European Union under the regulatory guidance of European Medical Association (EMA). Currently, there are three biosimilar versions of G-CSF available in the European market, namely Ratiograstim/Tevagrastim/Biograstim, Zarzio/Filgrastim Hexal and Nivestim/Pliva/Mayne filgrastim. Adding to the G-CSF biosimilars, the insulin biosimilars also showcase tremendous potential in the future. 

 

Global Biosimilars Market

BIOSIMILARS MARKET KEY BENEFITS 

  • The report on Biosimilars market 2020 is segmented in a strategic division to gain deeper insights into the market dynamics, size and understand the competitive environment of the overall market 
  • Financial market forecast is provided for the next eight years by considering 2013 as the base year
  • Comprehensive and quantitative data analysis about changing trends, intensifying competition and opportunities in biosimilars market 2020 are provided to make better business decisions
  • Porter’s Five Forces model and SWOT analysis of the overall Biosimilars industry is provided to help stakeholders gain strategic insights of the market
  • Deep dive analysis of key players and strategies adopted by them are expounded to provide valuable information on the top contenders in the market
  • Identification of key investment pockets for the market is strategically dealt to assist the stakeholders 

BIOSIMILARS MARKET KEY DELIVRABLES 

Global biosimilars/follow-on-biologics market is categorized into technology, product types, applications, services and geography.

BY TECHNOLOGY

  • Monoclonal Antibodies (MAb) Technology
  • Recombinant DNA Technology (rDNA technology)
  • Nuclear magnetic resonance (NMR) technology
  • Chromatography
  • Electrophoresis
  • Mass Spectrometry
  • Western Blotting
  • Bioassay

BY TYPES

  • Recombinant Non-Glycosylated Protein
    • Human Growth Hormone
    • Insulin
    • Interferon
    • Granulocyte colony stimulating factor (G-CSF)
    • Others
  • Recombinant Glycosylated Protein
    • Erythropoietin
    • Monoclonal antibodies
    • Others
  • Peptides
    • Octreotide
    • Desmopressin
    • Cyclosporine
    • Calcitonin
    • Eptifibatide
    • LH-RH (Leuprolide)
    • Nesiritide
    • Teriparatide
    • Bivalirudin
    • Enfuvirtide
    • Glucagon

BY APPLICATIONS

  • Blood disorders
    • Chemotherapy induce Anaemia
    • Hemophilia
    • Pulmonary embolism
  • Oncology diseases
    • Lungs cancer
    • Colorectal cancer
    • Breast cancer
    • Cervical cancer
    • Leukemia
    • Prostate cancer
  • Chronic and autoimmune diseases
    • Neutropenia
    • Multiple sclerosis
    • Cystic Fibrosis
    • Rheumatoid arthritis (RA)
    • Acromegaly
    • Leprosy
  • Growth hormone deficiencies
  • Others

BY SERVICES

  • Contract Research and Manufacturing Services (CRAMS)
  • Clinical Trials

BY GEOGRAPHY

  • North America
  • Europe
  • Asia-Pacific
  • LAMEA
Table Of Contents
* Pricing on the website is provided for single users licenses only. All reports will be provided in a PDF format for download. To purchase multi-user licenses, please contact us at +1-800-792-5285 or send an email to sales@alliedmarketresearch.com
Title/ Chapter Name Chapter Price

Chapter: 1 INTRODUCTION

1.1 Key Benefits
1.2 Key Market Segment
1.3 Key Audiences

1.3.1 Research Methodology
1.3.2 Primary Research
1.3.3 Secondary Research
1.3.4 Analyst tools and models

$0(SU) €0(SU) £0(SU)

Chapter: 2 EXECUTIVE SUMMARY

2.1 CXO perspective
2.2 Market beyond: what to expect by 2025

2.2.1 Moderate growth scenario
2.2.2 Rapid growth scenario
2.2.3 Diminishing growth scenario

$195(SU) €0(SU) £0(SU)

Chapter: 3 MARKET OVERVIEW

3.1 Market Definition
3.2 Diverse approach of global regulators towards biosimilars
3.3 Safety issues of  biosimilar drugs
3.4 Key Findings

3.4.1 Top factors impacting Biosimilars/Follow-On-Biologics market
3.4.2 Top winning strategies in the Biosimilars/Follow-On-Biologics market
3.4.3 Top investment pockets in Biosimilars/Follow-On-Biologics market

3.5 Regulation and Reimbursement scenario

3.5.1 Regulations in United States
3.5.2 Regulations in Europe
3.5.3 Regulation in Asia
3.5.4 Comparison of Biosimilar medicine guidelines

3.6 Emerging economies a hotspot for biosimilars market

3.6.1 “Brazil” a treasure for the biosimilar manufacturers
3.6.2 “China” the dragon market for biosimilars
3.6.3 “India” an early adopter of biosimilars

3.7 Porters five force analysis

3.7.1 Moderate bargaining of suppliers due to moderate switching cost
3.7.2 Moderate bargaining power of buyers due to lesser cost of switching
3.7.3 Higher threats from substitutes due to lower switching cost
3.7.4 Lower threats from new entrants due to technological and political barriers
3.7.5 Higher competition among players

3.8 Value chain analysis

3.8.1 Primary activities
3.8.2 Impact analysis of stakeholders involved in primary activities (2014-2020)
3.8.3 Supportive activities

3.9 Clinical trials

3.9.1 Title: Efficacy Study of Two Formulations of Erythropoietin
3.9.2 Title: Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anemia in Hematology and Oncology
3.9.3 Title: MATRIX: Measuring Neutralizing Antibodies in the Patients Treated With Interferon Beta 1a IM, in Mexico and Colombia
3.9.4 Title: An Extension Study to Demonstrate Long-Term Efficacy and Safety of CT-P13 When Co-administered With Methotrexate in Patient With Rheumatoid Arthritis Who Were Treated With Infliximab (Remicade or CT-P13) in Study CT-P13 3.1

3.10 Market Share analysis, 2013
3.11 Market Dynamics

3.11.1 Drivers

3.11.1.1 Growing pressure to reduce healthcare expenditure
3.11.1.2 Various blockbusters going off patent
3.11.1.3 High prevalence of chronic diseases among ageing population
3.11.1.4 Favorable intervention from the developing economies
3.11.1.5 Lower cost biosimilars drugs than original biologics

3.11.2 Restraints

3.11.2.1 High initial investment in research and development
3.11.2.2 Stringent regulations in developed economies to restrict investment
3.11.2.3 Medical Efficacy and Patient Safety

3.11.3 Opportunities

3.11.3.1 opportunities in Emerging economies
3.11.3.2 Emergence of bio-betters drugs

$595(SU) €0(SU) £0(SU)

Chapter: 4 GLOBAL BIOSIMILARS/FOLLO-ON-BIOLOGICS MARKET BY TECHNOLOGY

4.1 Monoclonal Antibodies (MAb) Technology

4.1.1 Drivers

4.2 Recombinant DNA Technology (rDNA technology)

4.2.1 Drivers
4.2.2 Restraints & Opportunities

4.3 Chromatography

4.3.1 Drivers & Opportunities
4.3.2 Liquid chromatography (LC)
4.3.3 Gas Chromatography (GC)
4.3.4 Protein sequencing
4.3.5 Drivers

4.4 Nuclear magnetic resonance (NMR) technology

4.4.1 Drivers

4.5 Electrophoresis

4.5.1 Drivers
4.5.2 Restraints & Opportunities
4.5.3 Gel Electrophoresis
4.5.4 Capillary Electrophoresis

4.6 MASS SPECTROMETRY

4.6.1 DRIVERS
4.6.2 RESTRAINTS

4.7 Western Blotting

4.7.1 Drivers

4.8 Bioassay

4.8.1 Drivers
4.8.2 Restraints
4.8.3 Techniques in Bioassay

4.8.3.1 Multiple Point Assays
4.8.3.2 Interpolation Method
4.8.3.3 Bracketing Method
4.8.3.4 Matching Bioassays

$495(SU) €0(SU) £0(SU)

Chapter: 5 GLOBAL BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET BY PRODUCT TYPE

5.1 Recombinant Non-Glycosylated Protein

5.1.1 Drivers
5.1.2 Human Growth Hormone

5.1.2.1 Key market trends
5.1.2.2 Key growth factors and opportunities
5.1.2.3 Market size & forecast

5.1.3 Insulin

5.1.3.1 Drivers & Opportunities
5.1.3.2 Key market trends
5.1.3.3 Key growth factors and opportunities
5.1.3.4 Market size & forecast

5.1.4 Interferon

5.1.4.1 Interferon Alfa
5.1.4.2 Interferon beta-1a
5.1.4.3 Interferon gamma
5.1.4.4 Key growth factors and opportunities
5.1.4.5 Market size & forecast

5.1.5 Granulocyte colony stimulating factor (G-CSF)

5.1.5.1 Key market trends
5.1.5.2 Market size & forecast

5.1.6 Others

5.1.6.1 Lepirudin
5.1.6.2 Interleukin – 2 (IL-2)
5.1.6.3 Anakinra

5.2 Recombinant Glycosylated Proteins

5.2.1 Drivers & Restraints
5.2.2 Erythropoietin

5.2.2.1 Key market trends
5.2.2.2 Key growth factors and opportunities
5.2.2.3 Market size & forecast

5.2.3 Monoclonal antibodies

5.2.3.1 Key market trends
5.2.3.2 Key growth factors and opportunities
5.2.3.3 Market size & forecast

5.2.4 Others

5.2.4.1 Follitropin
5.2.4.2 Thyrotropin
5.2.4.3 Urokinase
5.2.4.4 Glucocerebrosidase
5.2.4.5 Becaplermin
5.2.4.6 Factor VIIa
5.2.4.7 Factor VIII
5.2.4.8 Factor IX

5.2.5 Key market trends
5.2.6 Competitive scenario

5.3 Peptide s

5.3.1 Drivers
5.3.2 Restraints & Opportunities
5.3.3 Octreotide
5.3.4 Desmopressin
5.3.5 Cyclosporine
5.3.6 Calcitonin
5.3.7 Eptifibatide
5.3.8 LH-RH (Leuprolide)
5.3.9 Nesiritide
5.3.10 Teriparatide
5.3.11 Bivalirudin
5.3.12 Enfuvirtide
5.3.13 Glucagon

$895(SU) €0(SU) £0(SU)

Chapter: 6 GLOBAL BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET BY APPLICATIONS

6.1 Blood disorders

6.1.1 Drivers
6.1.2 Chemotherapy induce Anaemia

6.1.2.1 Drivers
6.1.2.2 RESTRAIN AND OPPORTINITIES

6.1.3 Hemophilia
6.1.4 Pulmonary embolism

6.1.4.1 DRIVER

6.2 Oncology diseases

6.2.1 Driver
6.2.2 Opportunities and restraints
6.2.3 Lungs cancer
6.2.4 Colorectal cancer
6.2.5 Breast cancer
6.2.6 Cervical cancer
6.2.7 Leukemia

6.2.7.1 Drivers

6.2.8 Prostate cancer

6.3 Chronic and autoimmune diseases

6.3.1 Diabetes

6.3.1.1 Drivers

6.3.2 Neutropenia
6.3.3 Multiple sclerosis

6.3.3.1 Drivers
6.3.3.2 Restraints and opportunities

6.3.4 Cystic Fibrosis
6.3.5 Rheumatoid arthritis (RA)

6.3.5.1 Drivers
6.3.5.2 Restraints

6.3.6 Acromegaly

6.3.6.1 Drivers

6.3.7 Leprosy

6.4 Growth hormone deficiency

6.4.1 Drivers

6.5 Others

6.5.1 Gaucher disease
6.5.2 Osteoporosis

$695(SU) €0(SU) £0(SU)

Chapter: 7 GLOBAL BIOSIMILARS / FOLLOW-ON-BIOLOGICS MARKET BY SERVICES

7.1 Contract Research and Manufacturing Services

7.1.1 Drivers
7.1.2 Restraints & Opportunities

7.2 Clinical trials

7.2.1 Drivers & Restraints
7.2.2 Phase I
7.2.3 Phase II
7.2.4 Phase III

$495(SU) €0(SU) £0(SU)

Chapter: 8 GLOBAL BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET BY GEOGRAPHIES

8.1 North America

8.1.1 Key market trends
8.1.2 Key growth factors and opportunities
8.1.3 Market size & forecast

8.2 Europe

8.2.1 Key market trends
8.2.2 Key growth factors and opportunities
8.2.3 Market size & forecast

8.3 Asia-Pacific

8.3.1 Key market trends

8.3.1.1 India

8.3.1.1.1 COMPETITIVE SCENARIO

8.3.1.2 China

8.3.1.2.1 COMPETITIVE SCENARIO

8.3.1.3 Australia

8.3.1.3.1 COMPETITIVE SCENARIO

8.3.2 Market size & forecast

8.4 LAMEA

8.4.1 Key market trends
8.4.2 Competitive scenario
8.4.3 Market size & forecast

$695(SU) €0(SU) £0(SU)

Chapter: 9 KEY PRODUCTS AND RECENT ACTIVITIES BY GEOGRAPHY

9.1 US

9.1.1 Hospira

9.1.1.1 Recent Activities

9.2 Europe

9.2.1 Stada Arzneimittel AG

9.2.1.1 Recent Activities

9.2.2 Hexal AG
9.2.3 Ratiopharm GmbH
9.2.4 Bioton

9.2.4.1 Recent Activities

9.2.5 Sandoz GmbH

9.2.5.1 Recent Activities

9.3 India

9.3.1 Dr.Reddy's Labs (DRL)

9.3.1.1 Recent Activities

9.3.2 Intas Pharmaceuticals Ltd.

9.3.2.1 Recent Activities

9.3.3 Wockhardt Limited

9.3.3.1 Recent Activities

9.3.4 Biocon Limited

9.3.4.1 Recent Activities

9.3.5 Shantha Biotechnics Limited

9.3.5.1 Recent Activities

9.3.6 Reliance Life Sciences

9.4 Korea

9.4.1 Dong-A Pharmaceutical Co., Ltd

9.4.1.1 Recent Activities

9.4.2 LG Life Sciences

9.4.2.1 Recent Activities

9.4.3 Celltrion Pharm, Inc.

9.4.3.1 Recent Activities

9.5 Others

9.5.1 Teva Pharmaceutical Industries Ltd.

9.5.1.1 Recent Activities

$496(SU) €0(SU) £0(SU)

Chapter: 10 COMPANY PROFILES

10.1 Novartis (Sandoz)

10.1.1 Company Overview
10.1.2 Company Snapshot
10.1.3 Business Performance
10.1.4 Key Strategies

10.1.4.1 Primary Strategies: Clinical Trials
10.1.4.2 secondary Strategies: approval

10.1.5 SWOT analysis

10.2 Synthon Pharmaceuticals, Inc.

10.2.1 Company Overview
10.2.2 Company Snapshot
10.2.3 Key Strategies

10.2.3.1 Primary Strategies: agreement
10.2.3.2 secondary Strategies: clinical trials

10.2.4 SWOT analysis

10.3 Teva Pharmaceutical Industries Ltd.

10.3.1 Company Overview
10.3.2 Company Snapshot
10.3.3 Business Performance
10.3.4 Key Strategies

10.3.4.1 Primary Strategies: approval
10.3.4.2 secondary Strategies: clinical trials

10.3.5 SWOT analysis

10.4 LG Life Sciences

10.4.1 Company Overview
10.4.2 Company Snapshot
10.4.3 Business Performance
10.4.4 Key Strategies

10.4.4.1 Primary Strategies: Collaboration

10.4.5 SWOT analysis

10.5 Celltrion

10.5.1 Company Overview
10.5.2 Company Snapshot
10.5.3 Business Performance
10.5.4 Key Strategies

10.5.4.1 Primary Strategies: approval

10.5.5 SWOT analysis

10.6 Biocon

10.6.1 Company Overview
10.6.2 Company Snapshot
10.6.3 Business Performance
10.6.4 Key Strategies

10.6.4.1 secondary Strategy: clinical trial

10.6.5 SWOT analysis

10.7 Hospira

10.7.1 Company Overview
10.7.2 Company Snapshot
10.7.3 Business Performance
10.7.4 Key Strategies

10.7.4.1 Primary Strategies: approval
10.7.4.2 secondary Strategies: clinical trials

10.7.5 SWOT analysis

10.8 Merck Serono (Merck Group)

10.8.1 Company Overview
10.8.2 Company Snapshot
10.8.3 Business Performance
10.8.4 Key Strategies

10.8.4.1 Primary Strategies: partnership and product launch

10.8.5 SWOT analysis

10.9 Biogen idec Inc.

10.9.1 Company Overview
10.9.2 Company Snapshot
10.9.3 Business Performance
10.9.4 Key Strategies

10.9.4.1 Primary Strategies: agreement and joint venture

10.9.5 SWOT analysis

10.10 Genentech (Roche Group)

10.10.1 Company Overview
10.10.2 Company Snapshot
10.10.3 Key Strategies

10.10.3.1 Primary Strategies: Investment and license

10.10.4 SWOT analysis

LIST OF TABLES
TABLE 1 BLOCKBUSTER PATENTS EXPIRATION BY 2014
TABLE 2 BIOSIMILARS MODERATE GROWTH SCENARIO MARKET REVENUE BY GEOGRAPHY, 2020-2025 ($MILLION)
TABLE 3 BIOSIMILARS RAPID GROWTH SCENARIO MARKET REVENUE BY GEOGRAPHY, 2020-2025 ($MILLION)
TABLE 4 BIOSIMILARS DIMINISHING GROWTH SCENARIO MARKET REVENUE BY GEOGRAPHY, 2020-2025 ($MILLION)
TABLE 5 BIOSIMILARS GUIDELINES ADOPTED BY REGIONS
TABLE 6 COMPARISON OF BIOSIMILAR MEDICINE GUIDELINES BY GEOGRAPHY (2013)
TABLE 7 BIOSIMILARS DEVELOPMENT 2013 (LATIN AMERICA)
TABLE 8 OFF GOING PATENTS 2013-2016
TABLE 9 PREVALENCE OF TOP TWO CHRONIC DISEASES (2013)
TABLE 10 BIOSIMILAR DEVELOPMENT STATUS (2013)
TABLE 11 GLOBAL BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY PRODUCT TYPES 2013-2020 ($MILLION)
TABLE 12 GLOBAL NON-GLYCOSYLATED PROTEIN BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY PRODUCT TYPES 2013-2020 ($MILLION)
TABLE 13 PATENTS STATUS FOR THE HUMAN GROWTH HORMONE (BIOLOGICS)
TABLE 14 PATENT EXPIRATION STATUS FOR HUMAN GROWTH HORMONE DURING 2014-2020 (BIOLOGICS)
TABLE 15 GLOBAL HGH BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY 2013-2020 ($MILLION)
TABLE 16 PATENTS APPROVED FOR INSULIN (BIOLOGICS)
TABLE 17 GLOBAL INSULIN BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY 2013-2020 ($MILLION)
TABLE 18 PATENTS APPROVED FOR INTERFERON (BIOLOGICS)
TABLE 19 PATENT EXPIRATION STATUS FOR INTERFERON DURING, 2014-2020 (BIOLOGICS)
TABLE 20 GLOBAL INTERFERON BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY 2013-2020 ($MILLION)
TABLE 21 PATENT EXPIRATION STATUS FOR G-CSF BIOSIMILARS DURING, 2014-2020 (BIOLOGICS)
TABLE 22 GLOBAL G-CSF BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY 2013-2020 ($MILLION)
TABLE 23 GLOBAL OTHER NON-GLYCOSYLATED PROTEIN BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY 2013-2020 ($MILLION)
TABLE 24 GLOBAL GLYCOSYLATED PROTEIN

€0(SU) £0(SU)

Global biosimilars/follow-on-biologics market in this report is segmented based on their functional bonding in which they are found such as glycosylated and non-glycosylated. Several pharmaceutical manufacturers are exploiting the lucrative opportunities available in this market. Presently, reference biologics are protected by IP (Intellectual Property) rights; however, the property protections for blockbuster drugs will soon expire, this will open up a platform for biosimilars manufacturers to gain dominance. Growing demand for over-the-counter (OTC) and prescription-based drugs would also cement the growth of the biosimilars industry in developing economies. Biosimilars versions of some monoclonal antibodies and granulocyte colony stimulating factors commercialized in the market have gained substantial foothold in the market in terms of revenue and growth. These medicines have outperformed their reference versions in terms of cost, performance and output. After successful market entry, the players operating in this market are now assured of its potential. This has lead to increase in their interest  for the research and development of novel biosimilar versions of the blockbuster drugs, which have soon to expire property protections. The biosimilars market would have a double digit growth rate and garner billions of dollars from the reference biopharmaceutical industry during 2013-2020. Developing economies such as China and India would act as the principle contributors to the growth of the biosimilar industry. This is due to the increase in healthcare expenditure, change in the quality of lifestyle and prevalence of chronic diseases in these regions. Additionally, under-developed economies such as those in Africa are also allowing biosimilars to be commercialized under the guidance of government regulations. Demand for biosimilar drugs in developed economies is still yet to gain popularity, as the consumer base in these countries shows an inclination towards branded drugs instead of biosimilars; hence, the biosimilars market is expecting sluggish growth in developed countries during the analysis period.

SINGLE USER
GROUP LICENSE
SITE LICENSE
GLOBAL LICENSE
$4515
$5325
$7350
$10680
LICENSE INFO
Users/Sharing
Restricted to one authorized user

Limited to 5 authorized users

Up to 25 users


unlimited within company / enterprise
Copy/Paste
Allowed up to 20% of the content
Allowed up to 25% of the content
Allowed up to 50% of the content
allowed 100%

Printing
One print only

Five Prints

Unlimited for internal use
Unlimited for internal use
Delivery Formats
ADDED BENIFITS
20% Free customization (Pre-sale)
16 Analyst hour support (Post Sale)
40 Analyst hour support (Post Sale)
160 hours of mini-consult
Free quarterly industry update
Free report on update (within 180 days)
MULTIPLE PURCHASE
Complimentary report with 2 reports
Complimentary report with 3 reports
Subscription Model
Have questions ?
connect
Need to add more ?
request

Single User
$4515
Group User
$5325
Site User
$7350
Global User
$10680
First time buyer ?
Check offers and discount
on this report
GET DISCOUNT
Need More Information
phone_n +1-503-894-6022

Help AMR help@alliedmarketresearch.com
Or
Send Enquiry
WHY ALLIED MARKET RESEARCH?
Infallible Methodology
To ensure high level data integrity, accurate analysis and impeccable forecasts
ANALYST SUPPORT
For complete satisfaction
CUSTOMIZATION
On-demand customization of scope of the report to exactly meet your needs
TARGETED MARKET
Targeted market view to eliminate redundant information to provide valued information and save time of the reader
RECENTLY VIEWED REPORTS
get_n
SIMILAR MARKET REPORTS
  • ...
    Companion diagnostics are in-vitro diagnostics that provide information about therapeutic responses of patients for a specific treatment. Companion diagnostics market is still nascent, and it is projected to reach $3.5 billion by 2020 from a base value of $1.1 billion in 2013, growing at a CAGR of 20% during 2014 to 2020. The global companion diagnostic market is segmented based on indication, technology and geography (North America, Europe, Asia Pacific and LAMEA). Geographically, LAMEA is the fastest growing region. The key drivers for this market are the increase in the discovery of biomarkers and co-development of drug and corresponding diagnostic. However, cost associated with developing drugs could impede the growth of this market.
    Jun 2014 | Price: $4515(SU) €0(SU) £0(SU) | View Details >>
  • ...
    In-vitro fertilization is an assisted reproductive technology, which involves a series of procedures for treating infertility problems. It involves the fertilization of the ovum in-vitro, followed by implantation of the embryo into a women’s uterus.
    Jan 2016 | Price: $4515(SU) €0(SU) £0(SU) | View Details >>
  • ...
    Intravenous Immunoglobulin (IVIG) is a sterile solution of antibodies collected from healthy donors, which is administered through the veins into the body. Currently, the immunoglobulin industry is growing on account of increasing FDA/EMA approvals and government support. IVIG usage against the conditions within the criteria (i.e. FDA/EMA approved indications) have increased greatly and the largest increase found in Chronic Inflammatory demyelinating polyneuropathy (CIDP), Hypogammaglobulinemia and immunodeficiency diseases.
    Apr 2015 | Price: $4515(SU) €0(SU) £0(SU) | View Details >>
  • ...
    Oncology/Anti-cancer drugs are used for treating various cancer types for improving and prolonging a patient’s survival time. Biological drugs, based on monoclonal antibodies (mAbs) would emerge as a preferred option for treating various cancer types, especially blood cancer (leukaemia).
    Feb 2016 | Price: $2500(SU) €0(SU) £0(SU) | View Details >>
ON DEMAND REPORTS
  • ...
    Non-invasive diagnostic is a process of identifying the disease conditions with minimal incision in body during diagnosis. The global market for diagnostic/in-vitro diagnostics valued at $49.2 billion in 2012, which shows potential for market growth, especially in chronic diseases. Non-invasive cancer diagnostics is gaining importance over conventional diagnosis due to increase in incidences of chronic cancer such as breast cancer, and lung cancer.
    May 2016 | View Details >>
  • ...
    Wearable medical devices are handheld monitoring tools used in identification and monitoring of disease. Due to the Increase in chronic diseases, patients are opting home healthcare as a cost effective and efficient way of treatment, rather than hospital services. Medical device market accounted for $240 billion in 2013. However, increase in incidence of chronic diseases restricts the growth of wearable medical device market.
    May 2016 | View Details >>
  • ...
    Cell surface markers are protein or antigenic determinants found on the surface of specific types of cells. They also act as a marker for identifying the specific type of cell. Determination of ligands or drug response in research activities is done through cell surface marker analysis.
    May 2016 | View Details >>
  • ...
    Cancer is one of the leading causes of death worldwide. According to the World Health Organization, about 8.2 million deaths occurred in 2012 due to cancer. The most common kinds of cancer which tend to result in death are lung cancer, liver cancer, stomach cancer, colorectal cancer, breast cancer and oesophageal cancer. Apart from the mature chemotherapy market, biotherapy has emerged as a new approach for cancer treatment.
    May 2016 | View Details >>